Abstract
Pefloxacin, a new fluoroquinolone, was given to 10 volunteers in single 400-mg oral doses repeated at 12-h intervals during 7 days. Serum, saliva, and feces samples were collected before and at appropriate intervals after the initiation of treatment. Drug concentrations were determined by bioassay. Qualitative and quantitative analyses of the saliva and fecal floras were performed. Mean concentrations in saliva (3.46 micrograms/ml on day 1 and 7.54 micrograms/ml on day 7) were closely related to levels in serum. High concentrations of pefloxacin were found in the feces (645 micrograms/g on day 8). No modification of oral flora was observed. In the fecal flora, members of the family Enterobacteriaceae were eliminated between days 2 and 8. The alterations in streptococci and anaerobic flora were not significant; Bacteroides fragilis was more resistant to pefloxacin after treatment. Clostridium difficile was not detected, and there was no overgrowth by yeasts. No side effects were observed.
MeSH Terms
Bacteria/drug effects
Bile/metabolism
Feces/analysis,microbiology
Female
Humans
Male
Mouth Mucosa/microbiology
Norfloxacin/analogs & derivatives,metabolism,pharmacology
Pefloxacin
Saliva/analysis
Chemicals
Pefloxacin
Norfloxacin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Janin N
Laboratoire de Bactériologie, Faculté de Médecine Alexis-Carrel, Antony, France.
Meugnier H
Desnottes J F
Woehrle R
Fleurette J
References (13)
13 references, click to expand
-
Selective and differential medium for isolation of Clostridium difficile.
J Clin Microbiol. 1979 Feb;9(2):214-9
PMID: 429542
-
[A new synthetic antibacterial : 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.)].
C R Seances Acad Sci III. 1981 Jan 5;292(1):37-40
PMID: 6786770
-
[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
Pathol Biol (Paris). 1982 Jun;30(6):394-7
PMID: 6810283
-
Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
Antimicrob Agents Chemother. 1984 Apr;25(4):463-72
PMID: 6587830
-
In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.
Antimicrob Agents Chemother. 1984 Apr;25(4):518-21
PMID: 6732221
-
Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.
Antimicrob Agents Chemother. 1984 Jul;26(1):110-1
PMID: 6236745
-
Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.
J Antimicrob Chemother. 1986 Apr;17 Suppl B:65-79
PMID: 3458699
-
Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.
Antimicrob Agents Chemother. 1984 Nov;26(5):757-61
PMID: 6517559
-
In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867).
Antimicrob Agents Chemother. 1984 Nov;26(5):785-6
PMID: 6517561
-
In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
J Antimicrob Chemother. 1985 Jan;15(1):39-44
PMID: 3156112
-
Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.
J Infect Dis. 1985 Jul;152(1):104-7
PMID: 3159811
-
Impact of oral ciprofloxacin on the faecal flora of healthy volunteers.
Infection. 1985 Nov-Dec;13(6):273-5
PMID: 2934338
-
The microbial flora of the rectal mucosa and faeces of patients with Crohn's disease before and during antimicrobial chemotherapy.
J Med Microbiol. 1984 Dec;18(3):335-45
PMID: 6334160